R&D | March 23, 2026
Altesa BioSciences unveils breakthrough data on Rhinovirus Drug at ICAR2026
Vapendavir is an oral, potent, broad-spectrum antiviral active against rhinoviruses and related respiratory enteroviruses
Vapendavir is an oral, potent, broad-spectrum antiviral active against rhinoviruses and related respiratory enteroviruses
RSM01, a preventive treatment targeting respiratory syncytial virus (RSV), was licensed earlier this month from the Gates Medical Research Institute
The trial enrolled patients with stage IV pancreatic cancer, where median life expectancy is just 6 to 12 months
Neupharma gains exclusive rights to develop and commercialize corticorelin for peritumoral brain edema
The trial’s primary goal is to evaluate vipoglanstat’s effect on endometriosis-related pain during non-menstrual days
The two companies will collaborate to evaluate Hopewell’s ttLNPs for clinical applications
The LIFT-PD study will enroll 75 Parkinson’s patients experiencing apathy across 16 sites in Germany, Bulgaria, Poland and Spain
The study will test the company’s lead product, ZI-MA4-1, in patients with advanced solid cancers
The alliance directly links VivaMed’s computational drug hypotheses with Syngene’s preclinical development capabilities
Acquisition expands Axol’s portfolio of iPSC-derived retinal organoid and retinal pigment epithelium (RPE) models
Subscribe To Our Newsletter & Stay Updated
